Squarepoint’s NovoCure NVCR Stock Holding History

Squarepoint’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-82,200	Closed	-$2.45M	–	5160
2024 Q4	$2.45M	Buy	+82,200	New	+$1.74M	﹤0.01%	2241
2023 Q4	–	Sell	-26,400	Closed	-$426K	–	4334
2023 Q3	$426K	Buy	+26,400	New	+$761K	﹤0.01%	2914

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Squarepoint's NVCR Position: Q1 2026 in Review

Squarepoint sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 53,045 shares — an estimated $686K sold.

Squarepoint first reported a position in NVCR in Q4 2017 and held it in 29 quarters. The position peaked at $16.2M in Q2 2021. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Squarepoint reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 53,045 NovoCure shares in Q1 2026, an estimated $686K.
Squarepoint first reported a position in NovoCure in Q4 2017 and held it in 29 quarters.
Squarepoint's NovoCure position peaked at $16.2M in Q2 2021.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.